Related Experiment Video
Updated: May 31, 2026
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Potential of histone deacetylase inhibitors for bladder cancer treatment
Nozomu Tanji1, Akira Ozawa, Tadahiko Kikugawa
1Department of Urology, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan. tanji@m.ehime-u.ac.jp
Abstract:
Bladder cancer incidence increases with age, presumably reflecting a cumulative exposure to carcinogens and ever-increasing life expectancy. While aberrant protein expression due to DNA mutations is an essential step during oncogenesis, one recent interest has been the role of epigenetic changes in regulating bladder tumor development. Because aberrant histone acetylation has been linked to malignant diseases in several cases, histone deacetylase inhibitors have great potential as new anticancer drugs owing to their ability to modulate transcription and induce differentiation and apoptosis. We herein review the current knowledge on epigenetic issues in bladder cancer, particularly regarding histone acetylation, and discuss its implications for understanding the molecular basis and treatment of this disease.
Insights
Epigenetic changes, specifically histone acetylation, play a crucial role in bladder cancer development. Histone deacetylase inhibitors show promise for treating this malignancy.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Bladder cancer incidence rises with age, suggesting cumulative carcinogen exposure.
- While DNA mutations are key, epigenetic alterations are increasingly recognized in bladder tumor development.
Purpose of the Study:
- To review current knowledge on epigenetic factors in bladder cancer.
- To focus on the role of histone acetylation in bladder tumorigenesis.
- To discuss implications for molecular understanding and treatment.
Main Methods:
- Literature review of epigenetic issues in bladder cancer.
- Focus on histone acetylation and its regulatory mechanisms.
- Analysis of histone deacetylase inhibitors' therapeutic potential.
Main Results:
- Aberrant histone acetylation is linked to various malignant diseases.
- Histone deacetylase inhibitors can modulate gene transcription.
- These inhibitors may induce cancer cell differentiation and apoptosis.
Conclusions:
- Epigenetic dysregulation, particularly histone acetylation, is significant in bladder cancer.
- Histone deacetylase inhibitors represent a promising therapeutic strategy for bladder cancer.
- Further research into epigenetic mechanisms can advance bladder cancer treatment.
